Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, Stötzer O, Foerster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Kreuzeder J, Guderian G, Fasching PA. Lüftner D, et al. Among authors: tesch h. Int J Cancer. 2024 Jul 1;155(1):128-138. doi: 10.1002/ijc.34912. Epub 2024 Mar 6. Int J Cancer. 2024. PMID: 38447007
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA. Tesch H, et al. Int J Cancer. 2019 Feb 15;144(4):877-885. doi: 10.1002/ijc.31738. Epub 2018 Oct 30. Int J Cancer. 2019. PMID: 29992557 Free PMC article. Clinical Trial.
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, Overkamp F, Einarson H, Hadji P, Tesch H, Ettl J, Lüftner D, Wallwiener M, Müller V, Janni W, Fehm TN, Schneeweiss A, Untch M, Pott D, Lux MP, Geyer T, Liedtke C, Seeger H, Wetzig S, Hartmann A, Schulz-Wendtland R, Belleville E, Wallwiener D, Beckmann MW, Brucker SY, Kolberg HC. Fasching PA, et al. Among authors: tesch h. Breast Cancer Res Treat. 2019 Jan;173(2):319-328. doi: 10.1007/s10549-018-5008-3. Epub 2018 Oct 15. Breast Cancer Res Treat. 2019. PMID: 30324275
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.
Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H. Hadji P, et al. Among authors: tesch h. J Bone Oncol. 2018 Oct 2;14:010-10. doi: 10.1016/j.jbo.2018.09.010. eCollection 2019 Feb. J Bone Oncol. 2018. PMID: 30515367 Free PMC article.
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.
Michel LL, Hartkopf AD, Fasching PA, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Volz B, Huebner H, Wimberger P, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN. Michel LL, et al. Among authors: tesch h. Cancers (Basel). 2020 Oct 17;12(10):3021. doi: 10.3390/cancers12103021. Cancers (Basel). 2020. PMID: 33080911 Free PMC article.
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Fehm TN, Lux MP, Schneeweiss A, Lüftner D, Janni W. Tesch H, et al. Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1115-1122. doi: 10.1055/a-1270-7481. Epub 2020 Nov 6. Geburtshilfe Frauenheilkd. 2020. PMID: 33173239 Free PMC article.
Update Breast Cancer 2021 Part 1 - Prevention and Early Stages.
Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching PA, Fehm TN, Hartkopf AD, Jackisch C, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Schütz F, Schulmeyer CE, Tesch H, Thomssen C, Uleer C, Untch M, Welslau M, Wöckel A, Wurmthaler LA, Würstlein R, Thill M. Stickeler E, et al. Among authors: tesch h. Geburtshilfe Frauenheilkd. 2021 May;81(5):526-538. doi: 10.1055/a-1464-0953. Epub 2021 May 3. Geburtshilfe Frauenheilkd. 2021. PMID: 34035547 Free PMC article.
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Marmé F, Solbach C, Michel L, Schneeweiss A, Blohmer JU, Huober J, Fasching PA, Jackisch C, Nekljudova V, Link T, Rhiem K, Rey J, Denkert C, Hanusch C, Tesch H, Lederer B, Loibl S, Untch M. Marmé F, et al. Among authors: tesch h. Eur J Cancer. 2021 Aug;153:203-212. doi: 10.1016/j.ejca.2021.05.027. Epub 2021 Jun 26. Eur J Cancer. 2021. PMID: 34186505
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
Hein A, Hartkopf AD, Emons J, Lux MP, Volz B, Taran FA, Overkamp F, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wurmthaler LA, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher CM, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Kolberg HC. Hein A, et al. Among authors: tesch h. Eur J Cancer. 2021 Sep;155:1-12. doi: 10.1016/j.ejca.2021.06.033. Epub 2021 Jul 23. Eur J Cancer. 2021. PMID: 34311211
348 results